One of the most common birth defects worldwide is hearing loss. Every 1,000 babies born worldwide are affected by permanent hearing loss in one or both ears. Hearing loss can significantly affect a baby's development.
CapitalBiotech has developed the Hereditary Deafness Gene Detection Assay using semiconductor sequencing technology. It can identify 100 mutant sites on 18 deafness-related genes such as GJB2, SLA26A4, GJB3, MT-RNR1, and others. This detection assay boasts an accuracy of over 99.9%.
The BioElectron Gene Squencer 4000 platform was developed in collaboration with Thermo Fisher. It can detect 384 samples simultaneously.
The Role of Microfluidic Platforms in Drug Development and TestingJuly 18, 2024In the dynamic landscape of drug development and testing, the advent of microfluidic technology stands as a revolutionary advancement. Among the frontrunners in this innovation is CapitalBio, a brand ...view
Microarray Platforms with Various Applications in Genetic ResearchJuly 18, 2024In recent years, the advancements in genetic research have revolutionized our understanding of the human genome. At the forefront of these developments is the Microarray Platform, a pivotal technology...view
Application Prospects of in Vitro Diagnostic TechnologyMarch 9, 2023The development of in vitro diagnostic (IVD) technologies has been rapid, spanning from genetic sequencing, SNP screening, point mutation gene diagnosis at the gene level, to the detection of various ...view